PubMed

Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir tablet formulation compared with soft gel capsules.

Schrader S, Chuck SK, Rahn LW, Parekh P, Emrich KG.

AIDS Res Ther. 2008 Sep 17;5:21.PMID: 18799008 [PubMed]Free PMC ArticleFree textRelated citations

Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ritonavir soft gel capsule to tablet in human immunodeficiency virus-infected patients.

Ofotokun I, Chuck SK, Schmotzer B, O'Neil KL.

AIDS Res Ther. 2009 Dec 22;6:29.PMID: 20028544 [PubMed]Free PMC ArticleFree textRelated citations

A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks.

Gathe J, da Silva BA, Cohen DE, Loutfy MR, Podzamczer D, Rubio R, Gibbs S, Marsh T, Naylor C, Fredrick L, Bernstein B.

J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):474-81.PMID: 19225400 [PubMed - indexed for MEDLINE]Related citations

Study of the gastrointestinal tolerance of a new tablet formulation of the lopinavir/ritonavir antiretroviral in HIV-infected patients.

de la Fuente JS, Granja V, Escobar I, de la Fuente EC, Moreno V, Rubio R.

J Acquir Immune Defic Syndr. 2009 Mar 1;50(3):294-8.PMID: 19194313 [PubMed - indexed for MEDLINE]Related citations

The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect.

Klein CE, Chiu YL, Awni W, Zhu T, Heuser RS, Doan T, Breitenbach J, Morris JB, Brun SC, Hanna GJ.

J Acquir Immune Defic Syndr. 2007 Apr 1;44(4):401-10.PMID: 17224848 [PubMed - indexed for MEDLINE]Related citations

Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children.

la Porte C, van Heeswijk R, Mitchell CD, Zhang G, Parker J, Rongkavilit C.

Antivir Ther. 2009;14(4):603-6.PMID: 19578247 [PubMed - indexed for MEDLINE]Related citations

Comparison of gastrointestinal tolerability and patient preference for treatment with the 625 mg and 250 mg nelfinavir tablet formulations.

Johnson M, Nieto-Cisneros L, Horban A, Arasteh K, Gonzalez-Garcia J, Artigas JG, Clotet B, Danise A, Landman R, Proll S, Snowden W, Foreman R, Smith P.

HIV Med. 2005 Mar;6(2):107-13.PMID: 15807716 [PubMed - indexed for MEDLINE]Related citations

Pharmacokinetics of lopinavir in HIV type-1-infected children taking the new tablet formulation once daily.

van der Flier M, Verweel G, van der Knaap LC, van Jaarsveld P, Driessen GJ, van der Lee M, Hartwig NG, Burger DM.

Antivir Ther. 2008;13(8):1087-90.PMID: 19195335 [PubMed - indexed for MEDLINE]Related citations

Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy.

Maitland D, Jackson A, Osorio J, Mandalia S, Gazzard BG, Moyle GJ; Epivir-Ziagen (EZ) Switch Study Team.

HIV Med. 2008 Oct;9(8):667-72. Epub 2008 Jul 8.PMID: 18631255 [PubMed - indexed for MEDLINE]Related citations

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.

Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard PM, Workman C, Dierynck I, Sekar V, Abeele CV, Lavreys L.

AIDS. 2009 Aug 24;23(13):1679-88.PMID: 19487905 [PubMed - indexed for MEDLINE]Related citations

Lopinavir/ritonavir pharmacokinetics in a substitution of high-dose soft-gelatin capsule to tablet formulation.

Hull MW, Harris M, Lima V, Guillemi S, Harrigan PR, Montaner JS.

J Clin Pharmacol. 2009 Feb;49(2):155-61.PMID: 19179294 [PubMed - indexed for MEDLINE]Related citations

[Longitudinal study on adherence, treatment satisfaction, and effectiveness of once-daily versus twice-daily antiretroviral therapy in a Spanish cohort of HIV-infected patients (CUVA study)]

Viciana P, Rubio R, Ribera E, Knobel H, Iribarren JA, Arribas JR, Pérez-Molina JA; Investigadores del Estudio CUVA.

Enferm Infecc Microbiol Clin. 2008 Mar;26(3):127-34. Spanish. PMID: 18358210 [PubMed - indexed for MEDLINE]Related citations

Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) Trial.

Udelson JE, Pressler SJ, Sackner-Bernstein J, Massaro J, Ordronneau P, Lukas MA, Hauptman PJ.

J Card Fail. 2009 Jun;15(5):385-93. Epub 2009 Feb 12.PMID: 19477398 [PubMed - indexed for MEDLINE]Related citations

Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.

Molina JM, Ait-Khaled M, Rinaldi R, Penco G, Baril JG, Cauda R, Soriano V, Pialoux G, Wire MB, Lou Y, Givens N, Craig C, Nichols WG, Barbosa I, Yeo J; TRIAD Study Group.

J Antimicrob Chemother. 2009 Aug;64(2):398-410. Epub 2009 Jun 10.PMID: 19515730 [PubMed - indexed for MEDLINE]Related citations

Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.

Mallolas J, Podzamczer D, Milinkovic A, Domingo P, Clotet B, Ribera E, Gutiérrez F, Knobel H, Cosin J, Ferrer E, Arranz JA, Roca V, Vidal F, Murillas J, Pich J, Pedrol E, Llibre JM, Dalmau D, García I, Aranda M, Cruceta A, Martínez E, Blanco JL, Lazzari E, Gatell JM; ATAZIP Study Group.

J Acquir Immune Defic Syndr. 2009 May 1;51(1):29-36.PMID: 19390327 [PubMed - indexed for MEDLINE]Related citations

Prognostic factors for virological response in antiretroviral therapy-naive patients in the MONARK Trial randomized to ritonavir-boosted lopinavir alone.

Flandre P, Delaugerre C, Ghosn J, Chaix ML, Horban A, Girard PM, Gladysz A, Cohen-Codar I, Van PN, Taburet AM, Rouzioux C, Delfraissy JF; MONARK Study Group.

Antivir Ther. 2009;14(1):93-7.PMID: 19320241 [PubMed - indexed for MEDLINE]Related citations

An assessment of patient preference and adherence to treatment with Wellbutrin SR: a web-based survey.

Granger AL, Fehnel SE, Hogue SL, Bennett L, Edin HM.

J Affect Disord. 2006 Feb;90(2-3):217-21. Epub 2005 Dec 15.PMID: 16360216 [PubMed - indexed for MEDLINE]Related citations

Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults.

Carr A, Ritzhaupt A, Zhang W, Zajdenverg R, Workman C, Gatell JM, Cahn P, Chaves R.

AIDS. 2008 Nov 12;22(17):2313-21.PMID: 18981770 [PubMed - indexed for MEDLINE]Related citations

Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy.

Chadwick EG, Pinto J, Yogev R, Alvero CG, Hughes MD, Palumbo P, Robbins B, Hazra R, Serchuck L, Heckman BE, Purdue L, Browning R, Luzuriaga K, Rodman J, Capparelli E; International Maternal Pediatric Adolescent Clinical Trials Group (IMPAACT) P1030 Team.

Pediatr Infect Dis J. 2009 Mar;28(3):215-9.PMID: 19209098 [PubMed - indexed for MEDLINE]Related citations

Difficult to swallow: patient preferences for alternative valproate pharmaceutical formulations.

Bhosle M, Benner JS, Dekoven M, Shelton J.

Patient Prefer Adherence. 2009 Nov 3;3:161-71.PMID: 19936158 [PubMed - in process]Free PMC ArticleFree textRelated citations